Two Sigma Investments
NEUP

Two Sigma Investments’s Neuphoria Therapeutics NEUP Stock Holding History

Two Sigma Investments’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,364
Closed -$12.6K – 3390
2024
Q2 		$12.6K Sell
1,364
-59
-4% -$642 ﹤0.01% 2955
2024
Q1 		$17.6K Sell
1,423
-1,183
-45% -$15.6K ﹤0.01% 2936
2023
Q4 		$46.3K Buy
+2,606
New +$74.4K ﹤0.01% 3003

Other funds holding NEUP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Two Sigma Investments's NEUP Position: Q3 2024 in Review

Two Sigma Investments sold out of Neuphoria Therapeutics (NEUP) in Q3 2024, closing a stake of 1,364 shares — an estimated $12.6K sold.

Two Sigma Investments first reported a position in NEUP in Q4 2023 and held it in 3 quarters. The position peaked at $46.3K in Q4 2023. 8 funds tracked by Wall St. Rank hold NEUP as of Q3 2024.

  • Two Sigma Investments reported no remaining Neuphoria Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Investments sold 1,364 Neuphoria Therapeutics shares in Q3 2024, an estimated $12.6K.
  • Two Sigma Investments first reported a position in Neuphoria Therapeutics in Q4 2023 and held it in 3 quarters.
  • Two Sigma Investments's Neuphoria Therapeutics position peaked at $46.3K in Q4 2023.
  • 8 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q3 2024.

Based on Two Sigma Investments's 13F filing for Q3 2024, filed 14 Nov 2024.